White House sounds the alarm on Covid-19 vac­cine, mon­o­clon­al sup­ply short­ages

4 years ago
FDA+
Coronavirus

Cy­ti­va opens doors at Cardiff site as part of $1.5B glob­al ex­pan­sion

4 years ago
Pharma
Manufacturing

Kansas court pre­lim­i­nar­i­ly ap­proves Vi­a­tris' $264M EpiPen set­tle­ment

4 years ago
Pharma
Law

No­vo Nordisk ‘think­ing big’ in re­newed col­lab­o­ra­tion with high-pro­file sci­en­tists Tra­ver­so, Langer

4 years ago
Deals

Mar­ket­ingRx roundup: Pfiz­er’s CEO talks pan­dem­ic pres­sure at SXSW; Ex­act Sci­ences teams with Katie Couric for ...

4 years ago
Pharma
Marketing

Pushed out of Eli Lil­ly in ethics scan­dal, Josh Smi­ley lands a top job at Zai Lab

4 years ago
People

Alec­tor presents PhII da­ta on lead de­men­tia drug; Chi­nese on­col­o­gy biotech nets mod­est Se­ries A+

4 years ago
News Briefing

Mer­ck suf­fers rare Keytru­da set­back as the block­buster fails a PhI­II prostate can­cer test with Lyn­parza

4 years ago
R&D

No­vo Nordisk, Gates Foun­da­tion pledge $90M to fund an­tivi­ral re­search for the next pan­dem­ic

4 years ago
R&D
Discovery

Ovid joins the re­struc­tur­ing move­ment, lay­ing off staff as Je­re­my Lev­in's crew re­fo­cus­es on epilep­sy

4 years ago
People
Pharma

Genome edit­ing prod­ucts: FDA rec­om­mends at least 15 years of fol­low-up af­ter clin­i­cal tri­als

4 years ago
Cell/Gene Tx
FDA+

Roiled by se­nior-lev­el ex­its, Jim Wil­son’s Pas­sage Bio re­trench­es, chop­ping back on staff as it ex­tends cash run­way

4 years ago
People
R&D

Root­ing for a come-from-be­hind win, Black­stone in­fus­es $330M in­to Sanofi's CD38 de­vel­op­ment plan

4 years ago
R&D

Anap­tys­Bio drops an­oth­er in­di­ca­tion for lead drug af­ter it fails a sec­ond PhII study in 12 months

4 years ago
R&D

Ei­sai finds an ex­it from Aduhelm, with small roy­al­ties if it ever nabs cov­er­age

4 years ago
Pharma

Af­ter rolling up noth­ing but pos­i­tive PhI­II da­ta for the FDA and EMA, Astel­las' drug for hot flash­es reg­is­ters a fail ...

4 years ago
R&D

Ex­elix­is throws in the tow­el on ear­ly-stage liv­er can­cer af­ter fi­nal read­out shows OS flop

4 years ago
R&D

Alzheimer’s group amps pub­lic pres­sure with ad cam­paign as Medicare de­ci­sion looms

4 years ago
Pharma
Marketing

Covid fears can still in­spire big mar­ket ral­lies for the mR­NA pi­o­neers — and fast fiz­zles

4 years ago
Marketing

As San­doz waits for No­var­tis to de­ter­mine its fate, the gener­ics play­er buys out a res­pi­ra­to­ry de­vice com­pa­ny

4 years ago
Deals
Pharma

Green­Light li­cens­es mR­NA shin­gles vac­cine to Serum In­sti­tute fol­low­ing a $10M in­vest­ment

4 years ago
Deals
Pharma

House com­mit­tee calls on DOJ to in­ves­ti­gate com­pa­nies' opi­oid set­tle­ment tax ben­e­fits

4 years ago
Pharma
Law

Ap­peals court sides with Bris­tol My­ers Squibb in years-long bat­tle with in­vestors over Op­di­vo fail

4 years ago
Pharma
Law

Grass­ley to FTC: In­ves­ti­gate the role of PBMs on out-of-pock­et costs

4 years ago
Pharma
First page Previous page 558559560561562563564 Next page Last page
A service from the Financial Times